Preclinical characterization of selective phosphodiesterase 10A inhibitors: A new therapeutic approach to the treatment of schizophrenia

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 2, 2008, Pages 681-690

  Schmidt, Christopher J ^a,b   Chapin, D S ^a   Cianfrogna, J ^a   Corman, M L ^a   Hajos, M ^a   Harms, J F ^a   Hoffman, W E ^a   Lebel, L A ^a   McCarthy, S A ^a   Nelson, F R ^a   Proulx LaFrance, C ^a   Majchrzak, M J ^a   Ramirez, A D ^a   Schmidt, K ^a   Seymour, P A ^a   Siuciak, J A ^a   Tingley III, F D ^a   Williams, R D ^a   Verhoest, P R ^a   Menniti, F S ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC GMP; MP 10; PAPAVERINE; PHOSPHODIESTERASE 10A INHIBITOR; PHOSPHODIESTERASE INHIBITOR; TP 10; UNCLASSIFIED DRUG; 2 (4 (PYRIDIN 4 YL 1 (2,2,2 TRIFLUOROETHYL) 1H PYRAZOL 3 YL)PHENOXYMETHYL)QUINOLINE SUCCINIC ACID; 2-(4-(PYRIDIN-4-YL-1-(2,2,2-TRIFLUOROETHYL)-1H-PYRAZOL-3-YL)PHENOXYMETHYL)QUINOLINE SUCCINIC ACID; DOPAMINE; PDE10A PROTEIN, MOUSE; PDE10A PROTEIN, RAT; PHOSPHODIESTERASE; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN FUNCTION; BRAIN REGION; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG STRUCTURE; HEARING ACUITY; HIPPOCAMPUS; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SIGNAL PROCESSING; ANIMAL; ANIMAL BEHAVIOR; BLOOD; BRAIN; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; FISCHER 344 RAT; GENETICS; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; STARTLE REFLEX;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CYCLIC AMP; CYCLIC GMP; DOPAMINE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PYRAZOLES; QUINOLINES; RATS; RATS, INBRED F344; RECOMBINANT PROTEINS; SCHIZOPHRENIA; STARTLE REACTION;

EID: 42449099422     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.132910     Document Type: Article

References (43)

1. American Psychiatric Association (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161:1-56.
2. Braff DL and Light GA (2004) Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology 174:75-85.
3. Cheer JF, Aragona BJ, Heien MLA, Seipel AT, Carelli RM, and Wightman RM (2007) Coordinated accumbal dopamine release and neural activity drive goal directed behavior. Neuron 54:237-244.
4. Coskran TM, Morton DG, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, and Stephenson DT (2006) Immunohistochemical localization of phosphodiesterase 10A, PDE10A, in multiple mammalian species. J Histochem Cytochem 54:1205-1213.
5. Coyle JT (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26:363-382.
6. Geyer MA, Krebs-Thomson K, Braff DL, and Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154.
7. Geyer MA, Swerdlow NR, Mansbach RS, and Braff DL (1990) Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 25:485-498.
8. Glavan G, Sket D, and Zivin M (2002) Modulation of neuroleptics activity of 9,10-didehydro-N-methyl-(2-propyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-parkinsonian rats. Mol Pharmacol 61:360-368.
9. Gottesman II and Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160:636-645.
10. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry, 153:321-330.
11. Guillin O, Abi-Dargham A, and Laruelle M (2007) Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 78:1-39.
12. Hajós M, Hurst RS, Hoffman WE, Krause M, Wall TM, Higdon NR, and Groppi VE (2005) The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 312:1213-1222.
13. Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, and Markou A (2002) The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 43:1199-1209.
14. Hoffman DC and Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side-effect liability. Psychopharmacology (Berl) 120:128-133.
15. Imre G, Salomons A, Jongsma M, Fokkema DS, Den Boer JA, and Ter Horst GJ (2006) Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviors and neurochemical changes in the dentate gyrus of the rat. Pharmacol Biochem Behav 84:392-399.
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
17. Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors and dopamine-glutamate interactions. Int Rev Neurobiol 78:69-108.
18. Jentsch JD and Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225.
19. Johnson KM and Jones SM (1990) Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 30:707-750.
20. Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160:13-23.
21. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stoup TS, et al. (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64:633-647.
22. Krause M, Hoffman WE, and Hajos M (2003) Auditory sensory gating in hippocampus and reticular thalamic neurons in anesthetized rats. Biol Psychiatry 53:244-253.
23. Laruelle M, Kegeles LS, and Abi-Dargham A (2003) Glutamate, dopamine and schizophrenia: from pathophysiology to treatment. Ann Natl Acad Sci 1003:138-158.
24. LonzeBE and Ginty DD (2002) Function and regulation of CREB family transcription factors in the nervous system. Neuron 35:605-623.
25. Mackin P, Bishop D, Watkinson H, Gallagher P, and Ferrier IN (2007) Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psych 191:23-29.
26. Marin C and Chase TN (1993) Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral sensitivity and receptor up-regulation. Eur J Pharmacol 231:191-196.
27. Menniti FS, Chappie TA, Humphrey JM, and Schmidt CJ (2007) Phosphodiesterase 10A (PDE10A) inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Invest Drug 8:54-59.
28. Newcomer JW (2005) Second generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl 1):1-93.
29. Ouagazzal AM, Jenck F, and Moreau JL (2001) Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? Psychopharmacology (Berl) 156:273-283.
30. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, et al. (2007) Activation of mGluR2/3 receptors: a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102-1107.
31. Paylor R and Crawley JN (1997) Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology 132:169-180.
32. Paxinos G and Watson C (1986) The Rat Brain in Stereotactic Coordinates, Academic Press, San Diego.
33. Ralph-Williams RJ, Lehmann-Masten V, Otero-Corchon, Low MJ, and Geyer MA (2002) Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 knock-out mice. J Neurosci 22:9604-9611.
34. Ralph-Williams RJ, Lehmann-Masten V, and Geyer MA (2003) D1 rather than D2 receptors disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology 28:108-118.
35. Seeger TF, Bartlett B, Coskran TM, Culp JM, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, et al. (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113-126.
36. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, et al. (2006a) Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 51:374-385.
37. Siuciak JA, Chapin DS, Harms JF, Lebel LA, James LC, McCarthy SA, Chambers LK, Shrikehande A, Wong SK, Menniti FS, et al. (2006b) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51:386-396.
38. Strick CA, Schmidt CJ, and Menniti FS (2006) PDE10A: a striatum enriched, dual-substrate phosphodiesterase, in Phosphodiesterases in Health and Disease (Francis S, Housley M, and Beavo J eds), pp 237-254, CRC Press, Boca Raton, FL.
39. Surmeier DJ, Ding J, Day M, Wang Z, and Shen W (2007) D1 and D2 dopamine receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30:228-235.
40. Verhoest PR, Helal CJ, Hoover DJ, and Humphrey JM (2006) inventors; Pfizer Products, Inc., assignee. Heteroaromatic quinoline compounds as phosphodiesterase inhibitors, their preparation, pharmaceutical compositions, and use in therapy. World patent WO 2006072828. 2006 Jul 13.
41. Wadenberg M-LG and Hicks PB (1999) The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862.
42. Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, Stephenson DT, Strick CA, Williams RD, and Menniti FS (2006) Cellular and subcellular localization of PDE10A, a striatal-specific phosphodiesterase. Neuroscience 139:597-607.
43. Zetterström T, Sharp T, and Ungerstedt U (1986) Effect of D1 and D2 receptor selective drugs on dopamine release and metabolism in rat striatum in vivo. Naunyn Schmiedebergs Arch Pharmacol 334:117-124.